Iktos, Merck collaborate on AI for new drug designs

By The Science Advisory Board staff writers

November 5, 2020 -- Artificial intelligence (AI) firm Iktos plans to collaborate with pharmaceutical giant Merck on AI for new drug design.

The partnership will allow Merck to use Iktos' generative design technology to develop a drug discovery program. Iktos' software creates virtual novel molecules for treating particular diseases. The company markets its AI technology as both services and software, it said; its AI software as a service (SaaS) software is called Makya and its AI SaaS platform, Spaya.

Merck invests $1B in Seagen
Merck has invested in oncology pharmaceutical developer Seagen in a deal worth $1 billion in equity investment.
New data from Merck, Kyorin shared to Pew's SPARK
Merck and Kyorin Pharmaceutical have shared antibiotic research data on the Pew Charitable Trusts' Shared Platform for Antibiotic Research and Knowledge...
Merck increases stake in Precigen
Merck is increasing its stake in Precigen from approximately 11.6% to 14.8% of outstanding shares through a convertible note with an outstanding principal...
Seattle Genetics, Merck partner on 2 oncology drug programs
Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately,...
How AI is speeding development of COVID-19 therapies
As the world is facing a new challenge in trying to both adapt to and defend itself against the novel coronavirus, artificial intelligence (AI) is offering...

Copyright © 2020 scienceboard.net

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter